Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of neoantigen-reactive T cells in bladder cancer
ChiCTR1800018421Phase 2Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jan 2019
- Modality
- Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Neoantigen-reactive T cells in bladder cancer, sponsored by Shenzhen Second People's Hospital. Primary endpoints: vital signs, routine blood test and 19 more. Started Jan 2019; status: recruiting.
02
Drugs
Neoantigen-reactive T cells
03
Conditions
bladder cancer
Beyond the preview
Go deeper on ChiCTR1800018421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018421.